Skip to main content

J&J's Motion To Toss The Oklahoma Opioid Lawsuit Denied

J&J's Motion To Toss The Oklahoma Opioid Lawsuit Denied

J&J's Motion To Toss The Oklahoma Opioid Lawsuit Denied

Introduction

On July 8, 2019, Oklahoma District Judge Thad Balkman denied Johnson & Johnson's (J&J) request to dismiss the opioid lawsuit due to lack of evidence.

A motion was filed last week by J&J to seek dismissal of the lawsuit claiming that the state failed to produce enough evidence to support its case. Both the parties were given an hour before the decision was rendered. J&J's lawyers said the nuisance law in the state did not apply, while the attorneys representing the state said that the defendants and their attorneys acted in a reprehensible manner.

According to Judge Balkman, the trial that began seven weeks ago, should continue and is expected to go on until late this month. Considering the evidence presented by the State, the judge determined there is sufficient evidence against the defendants, hence denied the motion for directed judgment.

Opioid lawsuits are consolidated under MDL No. 2804 (In Re: National Prescription Opiate Litigation) which is presided by U.S. District Judge Dan Polster.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

First Federal Bellwether Trial Set in Strattice Mesh Case

Categories: Hernia Mesh

Lawyers involved in federal Strattice hernia mesh litigation are scheduled to meet with the presiding judge in the U.S. District Court for the District of New Jersey to…

Tepezza Hearing Loss Trial Set for June 2026

Categories: Tepezza

The U.S. District Judge overseeing all federal Tepezza lawsuits has postponed the start of the first bellwether trial by 60 days.

This decision comes as attorneys…

FDA Moves to Restrict Dangerous 7-OH Opioid Products

Categories: Opioids

In a significant move to combat the ongoing opioid crisis, the U.S. Food and Drug Administration (FDA) has recommended a scheduling action under the Controlled Substances Act (CSA) to regulate certain products containing 7-hydroxymitragynine (7-…

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!